Beam sets hopes on accelerated approval of AATD gene therapy
Beam presented data from the Phase I/II trial of BEAM-302 where it showed disease-modifying qualities.
AD/PD 2026: Aspen’s sasineprocel reaches primary endpoint in Phase I/IIa ASPIRO trial
LB Pharmaceuticals commences Phase III schizophrenia trial
AD/PD 2026: Three-year data confirms slow amyloid re-accumulation following Kisunla treatment completion
C4 Therapeutics begins dosing in Phase Ib trial for multiple myeloma
Ocugen’s GA gene therapy garners mixed sentiments on 12-month Phase II readout
Analysis
View More
Themes
View MoreKidney disease risk higher after Covid infection than after influenza infection
Researchers at the Penn State College of Medicine sought to determine the effects of Covid-19 and influenza on the risk of acute and chronic kidney disease.
More themes
Data Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View more
Digital Magazine
View MorePharma Technology Focus Magazine
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Oncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs